ChemoCentryx Says Glaxo's Results from Study of Vercirnon Did Not Meet Primary Endpoint Print E-mail
By Staff and Wire Reports   
Friday, 23 August 2013 19:35
Below is a look at some of the headlines for companies that made news in the healthcare sector on August 23, 2013.

ChemoCentryx, Inc. (Nasdaq: CCXI) reports GlaxoSmithKline (NYSE: GSK) announced today that the first of four Phase III studies, the SHIELD-1 study, investigating vercirnon, an inhibitor of the chemokine receptor known as CCR9, in patients with moderate-to-severe Crohn's disease did not achieve the primary endpoint of improvement in clinical response and the key secondary endpoint of clinical remission.

The rates of serious adverse events and withdrawals due to adverse events were similar among all treatment groups including the placebo group, with a trend in dose-dependent increases in overall adverse event rates. GSK has indicated that it intends to continue to explore the safety and efficacy results to inform decisions about the clinical development program for vercirnon. New recruitment and dosing in the ongoing clinical program has been suspended pending further review of the SHIELD-1 results.



Also Friday:



Arrhythmia Research Technology, Inc. (NYSE MKT: HRT), announced, on August 20, 2013, it received notice from the NYSE MKT LLC that it is not in compliance with certain of the Exchange's continued listing standards as set forth in Sections 134 and 1101 of the Exchange's Company Guide as a result of the failure to file its interim report on Form 10-Q on a timely basis.

RedChip Companies, Inc., today announced it has issued a research profile on Cancer Genetics, Inc. (Nasdaq:CGIX), an emerging leader in DNA-based cancer diagnostics and services.

Cerebain Biotech Corp., a subsidiary of Discount Dental Materials, Inc. (OTCBB: DDOO), announced that medical device product development company, Sonos Models, Inc. (“Sonos”), has provided additional photo of the first prototype of the Company’s medical device solution for the treatment of Alzheimer’s disease utilizing the Omentum.

Daxor Corporation, (NYSE MKT: DXR) an investment company with medical instrumentation and biotechnology operations, will be filing a Form N-CSR later today disclosing its schedule of portfolio holdings as of June 30, 2013.

Easton Pharmaceuticals, Inc. (OTC:EAPH), a specialty pharmaceutical company that designs, develops, and markets a premium array of topically-delivered therapeutic healthcare products, today announced updates to its Canadian and United States Medical Marijuana initiatives.

HPIL Holding (OTCQB: HPIL) is pleased to announce that its wholly owned subsidiary HPIL GLOBALCOM Inc., on August 20, 2013, entered into a Cooperation Agreement with 2EVOLUTION STUDIOS, a private company focused on investing in the communication sector.

LeMaitre Vascular, Inc. (Nasdaq:LMAT) is presenting at the 6th Annual Barrington Research Growth Conference at the Four Seasons Hotel in Chicago, IL. JJ Pellegrino, Chief Financial Officer, will provide an update on the Company on Wednesday, September 4, 2013.

Manhattan Scientifics (OTCQB:MHTX)
announced today that Loraine Upham has been engaged as a consultant to support its cancer team.

Nuvilex, Inc. (OTCQB: NVLX)
, an international biotechnology company and former provider of natural products, as well as cell and gene therapy solutions for the treatment of diseases, announced today that the Company has restructured corporate operations in an effort to focus on its biotechnology core businesses.

XOMA Corporation (Nasdaq:XOMA)
announced today the closing of the offering of 8,736,187 shares of its common stock, including 1,139,502 shares of common stock that were issued upon the exercise of the underwriters' over-allotment option to purchase additional shares, at a price to the public of $3.62 per share.

Yew Bio-Pharm Group, Inc. (OTCBB: YEWB)
, a major grower and seller of yew trees, yew raw materials used in the manufacture of traditional Chinese medicine and products made from yew timber in China, today announced that S&P Capital IQ has commenced coverage on Yew Bio-Pharm Group.



"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!
 

Newsletter